A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients

Authors
Publication date
1 January 2011
Publisher
Doi
    View on PubMed

    Abstract

    Sorafenib has demonstrated single agent activity in non-small cell (NSCLC) and small cell lung cancer (SCLC). Carboplatin/pemetrexed (CbP) and cisplatin/etoposide (PE) are commonly used in the treatment of these diseases

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Carolina Digital Repository

      redirect
      oaicdr.lib.unc.edu:9880vz828
      Last time updated on 24/11/2020